All Oncology News

ODAC supported the approval of necitumumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer.

ORIEN partnership founded by The Ohio State University Comprehensive Cancer Center and Moffitt Cancer Center adds three new members, widens patient access to precision clinical trials.

Britten continues as Associate Director for Clinical Investigations for the MUSC Hollings Cancer Center.

Philip McCarthy, MD, explains the significance of the updated CALGB 100104 study results.

Despite the overall rate increase in breast-conserving therapy among women with early-stage breast cancer, economic and geographic factors have left some patients behind.

Neal Shore, MD, recently visited the OncLive News Network studios to discuss his role in LUGPA and provide his clinical insights about skeletal complications and the sequencing of radium-223.

Rolling submission of a new drug application for rociletinib has been initiated for patients with EGFR T790M-positive metastatic non–small cell lung cancer following prior treatment with an EGFR-targeted therapy.

The FDA has extended the review period for the MEK inhibitor cobimetinib in combination with the BRAF inhibitor vemurafenib (Zelboraf) for patients with BRAFV600 mutation-positive advanced melanoma by 3 months, making the new decision date November 11, 2015.

Partnership forms to share the latest news about Sarah Cannon's innovative clinical practices and wide-ranging clinical trial programs for cancer.

OncLive® will team with Sarah Cannon, the global cancer enterprise of Hospital Corporation of America, as it further expands its Strategic Alliance Partnership Program for raising awareness of cancer treatment and research.

Limited data exist regarding optimal patient selection and sequencing of radium-223 relative to other approved treatments for patients with metastatic castration-resistant prostate cancer.

A randomized study is underway to determine if the combination of sipuleucel-T (Provenge) and radium-223 (Xofigo) may improve outcomes in patients with metastatic castration-resistant prostate cancer.

Celgene has entered into a 10-year collaboration with the cellular immunotherapy company Juno Therapeutics, which includes an initial $1 billion payment.

Bone marrow failure may occur following treatment with radium-223 in a portion of patients with metastatic castration-resistant prostate cancer who have high skeletal tumor burden.

Combining the CD30-directed antibody-drug conjugate brentuximab vedotin with R-CHOP yielded objective responses in 80% of patients with advanced DLBCL in a phase II trial.

John P. Leonard, MD, discusses the phase III SELENE and AUGMENT trials, along with smaller investigations, which hope to uncover more efficacious treatments for patients with NHL.

Howard L. Kaufman, MD, discusses the rapidly advancing immunotherapy armamentarium in melanoma.

Treatment with CPX-351 led to a relative improvement in induction response of over 40% compared with conventional 7+3 cytarabine/daunorubicin in patients with secondary acute myeloid leukemia.

OncLive sat down with Jason J. Luke, MD, discusses the key areas in the treatment of melanoma discussed at the 2015 ASCO Annual Meeting included selecting appropriate immunotherapy regimens based on PD-L1 status and improving surgical practices.

The FDA has assigned a priority review designation to MM-398 in combination with 5-fluorouracil and leucovorin for patients with metastatic pancreatic cancer following treatment with a gemcitabine-based therapy.

Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine will be one of the sites offering the landmark precision medicine trial, NCI-MATCH – a trial that will open to patient enrollment in July.

Erin N. Kobetz, PhD, MPH, has been named Senior Associate Dean for Health Disparity at the University of Miami Miller School of Medicine.

Invention opens pathway for more personalized treatments.

OncLive spoke with Bruce D. Cheson, MD, to gain a deeper understanding about the significance of the GADOLIN study results.

Ricardo J. Komotar, M.D., Director of Surgical Neuro-oncology at UHealth – University of Miami Health System, is the first neurosurgeon in Miami-Dade and Broward counties to remove a brain tumor using the NICO BrainPath system.

OncLive spoke with Jeffrey Jones, MD, MPH, to better understand the Study 119 results, as well as the role idelalisib and other novel targeted agents will play in CLL going forward.

Lead author Asher A. Chanan-Khan, MD, discusses the HELIOS trial, in which adding ibrutinib to bendamustine and rituximab lowered the risk of disease progression by 80% in patients with CLL.

Chemotherapy-free neoadjuvant treatment with trastuzumab emtansine demonstrated a pathological complete response rate of 40.5% in patients with HER2+ and HR+ early breast cancer.

Ruth M. O'Regan, MD, discusses two of her studies in HER2-positive breast cancer presented at ASCO 2015.

ASCO unveiled a drug valuation methodology that found no added health benefit from a $9200 per month trial chemotherapy regimen compared with an $800 per month standard-of-care therapy.